 Connection
Paul Buehler to Hemopexin
This is a "connection" page, showing publications Paul Buehler has written about Hemopexin.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.469 |
|
|
|
-
Buehler PW, Swindle D, Pak DI, Ferguson SK, Majka SM, Karoor V, Moldovan R, Sintas C, Black J, Gentinetta T, Buzzi RM, Vallelian F, Wassmer A, Edler M, Bain J, Schu D, Hassell K, Nuss R, Schaer DJ, Irwin DC. Hemopexin dosing improves cardiopulmonary dysfunction in murine sickle cell disease. Free Radic Biol Med. 2021 11 01; 175:95-107.
Score: 0.704
-
Karnaukhova E, Owczarek C, Schmidt P, Schaer DJ, Buehler PW. Human Plasma and Recombinant Hemopexins: Heme Binding Revisited. Int J Mol Sci. 2021 Jan 26; 22(3).
Score: 0.675
-
Buehler PW, Karnaukhova E. When might transferrin, hemopexin or haptoglobin administration be of benefit following the transfusion of red blood cells? Curr Opin Hematol. 2018 11; 25(6):452-458.
Score: 0.578
-
Yalamanoglu A, Deuel JW, Hunt RC, Baek JH, Hassell K, Redinius K, Irwin DC, Schaer DJ, Buehler PW. Depletion of haptoglobin and hemopexin promote hemoglobin-mediated lipoprotein oxidation in sickle cell disease. Am J Physiol Lung Cell Mol Physiol. 2018 11 01; 315(5):L765-L774.
Score: 0.568
-
Lucero MJ, Lisk C, Cendali F, Swindle D, Setua S, Thangaraju K, Pak DI, O'Boyle Q, Lu S, Tolson R, Zaeske S, Rana N, Khan S, Westover N, DavizonCastillo P, George G, Hassell K, Nuss R, Brinkman N, Gentinetta T, Palmer AF, D'Alessandro A, Buehler PW, Irwin DC. Targeting lung heme iron by aerosol hemopexin adminstration in sickle cell disease pulmonary hypertension. Free Radic Biol Med. 2025 Mar 01; 229:458-473.
Score: 0.223
-
Vallelian F, Buehler PW, Schaer DJ. Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics. Blood. 2022 10 27; 140(17):1837-1844.
Score: 0.191
-
Buzzi RM, Owczarek CM, Akeret K, Tester A, Pereira N, Butcher R, Brügger-Verdon V, Hardy MP, Illi M, Wassmer A, Vallelian F, Humar R, Hugelshofer M, Buehler PW, Gentinetta T, Schaer DJ. Modular Platform for the Development of Recombinant Hemoglobin Scavenger Biotherapeutics. Mol Pharm. 2021 08 02; 18(8):3158-3170.
Score: 0.175
-
Deuel JW, Vallelian F, Schaer CA, Puglia M, Buehler PW, Schaer DJ. Different target specificities of haptoglobin and hemopexin define a sequential protection system against vascular hemoglobin toxicity. Free Radic Biol Med. 2015 Dec; 89:931-43.
Score: 0.117
-
Schaer DJ, Buehler PW. Cell-free hemoglobin and its scavenger proteins: new disease models leading the way to targeted therapies. Cold Spring Harb Perspect Med. 2013 Jun 01; 3(6).
Score: 0.099
-
Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood. 2013 Feb 21; 121(8):1276-84.
Score: 0.096
-
Yalamanoglu A, Dubach IL, Schulthess N, Ingoglia G, Swindle DC, Humar R, Schaer DJ, Buehler PW, Irwin DC, Vallelian F. Agonistic Anti-CD40 Antibody Triggers an Acute Liver Crisis With Systemic Inflammation in Humanized Sickle Cell Disease Mice. Front Immunol. 2021; 12:627944.
Score: 0.043
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|